SOUTH PLAINFIELD,
N.J., July 11, 2023 /PRNewswire/ -- PTC
Therapeutics, Inc. (NASDAQ: PTCT), announced today that the
company will provide a virtual presentation on PKU including
discussion of the current therapeutic and commercial landscape with
an expert key opinion leader. In addition, the company will discuss
the sepiapterin clinical program followed by a Q&A session. The
event will occur on Wednesday, July
19, from 12 to 1:30 p.m. ET.
Presenters will include Ania C. Muntau, MD, Professor of
Pediatrics, Chair, University Children's Hospital, University
Medical Center, Hamburg Eppendorf, Germany, and PTC senior management.
Conference Call and Webcast Information
To access the call by phone, please click here to register and
you will be provided with dial-in details. To avoid delays, we
recommend participants dial in to the conference call 15 minutes
prior to the start of the call. The webcast conference call can be
accessed on the Investor section of the PTC website
at https://ir.ptcbio.com/events-presentations. A replay of the
call will be available approximately two hours after completion of
the call and will be archived on the company's website for 30 days
following the call.
About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company focused on the discovery,
development and commercialization of clinically differentiated
medicines that provide benefits to patients with rare disorders.
PTC's ability to innovate to identify new therapies and to globally
commercialize products is the foundation that drives investment in
a robust and diversified pipeline of transformative medicines.
PTC's mission is to provide access to best-in-class treatments for
patients who have little to no treatment options. PTC's strategy is
to leverage its strong scientific and clinical expertise and global
commercial infrastructure to bring therapies to patients. PTC
believes this allows it to maximize value for all its stakeholders.
To learn more about PTC, please visit us
at www.ptcbio.com and follow us on Facebook, Instagram,
LinkedIn and Twitter at @PTCBio.
For More Information:
Investors:
Kylie
O'Keefe
+1 (908) 300-0691
kokeefe@ptcbio.com
Media:
Jeanine
Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-announces-virtual-presentation-on-phenylketonuria-pku-and-sepiapterin-301874444.html
SOURCE PTC Therapeutics, Inc.